| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","as_of":"2026-04-08T09:32:58.864102+00:00","canonical_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","article_chars":4347,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_a2d5f1db7d8deb27","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-08T09:39:27.858694+00:00","extraction_method":"heuristic","fetched_description":"Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.","fetched_title":"Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? | Nasdaq","final_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock","source_event_id":"evt_10a10922fbaa","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"ac54bf4d4234f7b3","kind":"new_listings","published_at":"2026-04-08T07:44:00+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 08, 2026"],"entities":[{"asset_class":"equity","name":"Artivion, Inc.","relevance":"high","symbol":"AORT","type":"company"},{"asset_class":"equity","name":"Endospan Ltd.","relevance":"medium","symbol":"","type":"company"},{"asset_class":"other","name":"NEXUS Aortic Arch System","relevance":"high","symbol":"","type":"product/system"},{"asset_class":"other","name":"FDA","relevance":"high","symbol":"","type":"regulator"},{"asset_class":"equity","name":"Treace Medical Concepts, Inc.","relevance":"low","symbol":"TMCI","type":"company"}],"event_type":"price_action","information_gaps":["The article does not provide the exact trading volume figure or the specific \"normal session\" baseline used to define above-average volume.","The article does not specify whether the FDA approval is for a specific indication or the full scope of the approval beyond \"premarket approval\" for the NEXUS Aortic Arch System.","No explicit statement is provided about the magnitude of earnings estimate revisions beyond \"remained unchanged\" over the last 30 days.","The article does not quantify how much of the price move is attributable to the FDA news versus other factors (it states attribution but not a causal breakdown)."],"key_facts":["AORT shares closed at $35.22 after rising 5.3% in the last trading session.","The price move was accompanied by above-average trading volume (\"far more shares changing hands than in a normal session\").","The article states AORT had a 7.3% loss over the past four weeks.","The article attributes the increase to FDA premarket approval for the NEXUS Aortic Arch System developed by Endospan Ltd.","The FDA approval is described as entitling Artivion to exercise an option to acquire Endospan at any time within 90 days of receiving the notice of FDA approval.","Upcoming quarterly earnings are expected to be $0.06 per share, unchanged versus the year-ago quarter.","Revenues are expected to be $115.95 million, up 17.1% versus the year-ago quarter.","The consensus EPS estimate for the quarter is stated to have remained unchanged over the last 30 days.","The article states that a stock's price usually doesn't keep moving higher without a trend in earnings estimate revisions.","AORT is stated to carry a Zacks Rank #3 (Hold)."],"numeric_claims":[{"label":"Price change (last session)","value":"5.3%"},{"label":"Close price","value":"$35.22"},{"label":"Loss over past four weeks","value":"7.3%"},{"label":"Option exercise window after FDA notice","value":"90 days"},{"label":"Expected EPS (upcoming quarter)","value":"$0.06 per share"},{"label":"EPS change vs year-ago quarter","value":"0% (no change stated)"},{"label":"Expected revenue (upcoming quarter)","value":"$115.95 million"},{"label":"Revenue growth vs year-ago quarter","value":"17.1%"},{"label":"EPS estimate revision window","value":"30 days"},{"label":"Zacks Rank","value":"#3 (Hold)"}],"primary_claim":"Artivion (AORT) shares surged 5.3% to $35.22 on above-average volume following FDA premarket approval for the NEXUS Aortic Arch System, which also triggers an option for Artivion to acquire Endospan within 90 days.","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"Artivion (AORT) shares rose 5.3% to close at $35.22 on above-average volume, attributed to FDA premarket approval for the NEXUS Aortic Arch System. The article notes consensus EPS estimate revisions have been unchanged over the last 30 days, suggesting limited evidence of further near-term strength.","topics":["FDA approval","medical devices","earnings estimate revisions","stock price move","Zacks Rank"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.","tickers":["AORT"],"title":"Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?","url":"https://www.nasdaq.com/articles/artivion-aort-soars-53-further-upside-left-stock"}... |